The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes - Trial NCT06408532
Access comprehensive clinical trial information for NCT06408532 through Pure Global AI's free database. This Phase 4 trial is sponsored by Peking University People's Hospital and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 256 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University People's Hospital
Timeline & Enrollment
Phase 4
Apr 30, 2024
Feb 28, 2025
Primary Outcome
Hemoglobin A1c (HbA1c)
Summary
The study aims to evaluate the efficacy and safety of IDegLira in type 2 diabetes who have
 failed premixed insulin therapy. The study plans to enroll 256 participants with inadequate
 glycemic control despite twice-daily subcutaneous injections of premixed insulin and
 metformin. Participants will be randomly assigned to either the premixed insulin dose
 optimization group (control group) or IDegLira once daily group, and the difference in change
 in glycated hemoglobin levels from baseline to 16 weeks of treatment will be assessed between
 the two groups.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06408532
Non-Device Trial